TABLE 1.
Patient demographics and baseline disease characteristics
| Variablea | LY IGlar (n = 359) | IGlar (n = 177) | Total (N = 536) |
|---|---|---|---|
| Age, years | 58.3 (9.6) | 59.5 (8.9) | 58.7 (9.4) |
| Median (range) | 59.0 (27–83) | 60.0 (30–80) | 59.0 (27–83) |
| ≥65, n (%) | 95 (26.5) | 58 (32.8) | 153 (28.5) |
| Males, n (%) | 209 (58.2) | 98 (55.4) | 307 (57.3) |
| Race, n (%) | |||
| Asian | 359 (100) | 177 (100) | 536 (100) |
| Body weight, kg | 69.10 (11.58) | 68.35 (11.72) | 68.86 (11.62) |
| Body mass index, kg/m2 | 25.363 (2.988) | 25.411 (3.378) | 25.379 (3.119) |
| HbA1c | |||
| % | 8.42 (1.04) | 8.39 (0.92) | 8.41 (1.00) |
| mmol/mol | 68.6 (11.4) | 68.2 (10.1) | 68.4 (11.0) |
| HbA1c at baseline, n (%) | |||
| <8.5% (<69 mmol/mol) | 204 (56.8) | 100 (56.5) | 304 (56.7) |
| ≥8.5% (≥69 mmol/mol) | 155 (43.2) | 77 (43.5) | 232 (43.3) |
| FBG at baselineb | |||
| mg/dL | 169.0 (39.17) | 163.1 (39.04) | 167.0 (39.19) |
| mmol/L | 9.38 (2.174) | 9.05 (2.167) | 9.27 (2.175) |
| Duration of diabetes, years | 10.09 (5.47) | 10.69 (5.94) | 10.29 (5.63) |
| Number of OAMs before randomization, n (%) | |||
| 2 | 233 (64.9) | 126 (71.2) | 359 (67.0) |
| 3 | 118 (32.9) | 46 (26.0) | 164 (30.6) |
| 4 | 8 (2.2) | 5 (2.8) | 13 (2.4) |
| Entry use of insulin secretagogues, n (%) | |||
| Sulphonylureas | 254 (70.8) | 129 (72.9) | 383 (71.5) |
| Meglitinide | 27 (7.5) | 12 (6.8) | 39 (7.3) |
| Neither | 78 (21.7) | 36 (20.3) | 114 (21.3) |
Abbreviations: FBG, fasting blood glucose; IGlar, insulin glargine; LY IGlar, LY2963016 insulin glargine; OAM, oral antihyperglycaemic medication.
a
Variables are summarized as mean (standard deviation) unless stated.
b
By self‐monitored blood glucose.